The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Corticosteroid Usage in Stage 4 Pulmonary Sarcoidosis Could Offer Little Benefit, Pose Significant Health Risk

Systemic Corticosteroid Usage in Stage 4 Pulmonary Sarcoidosis Could Offer Little Benefit, Pose Significant Health Risk

November 16, 2016 • By Josna Haritha, MD, MPH, Derick N. Jenkins, MD, & Manpreet Malik, MBBS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Depending on stage, severity and rate of progression of disease, systemic corticosteroids are commonly used to treat pulmonary sarcoidosis. However, a review of the literature suggests they have limited usefulness in advanced stage IV pulmonary sarcoidosis. Once sarcoidosis has advanced to this degree, steroid use may unnecessarily expose a patient to life-threatening complications, as demonstrated in this report.

You Might Also Like
  • E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
Explore This Issue
November 2016

Case Presentation

A 41-year-old man presented to the emergency department with massive hemoptysis that resulted in a cardiac arrest. With emergent resuscitation, return of spontaneous circulation was achieved, and the patient was intubated for hypoxic respiratory failure, requiring mechanical ventilation. His medical history was significant for a 10-year history of pulmonary sarcoidosis and steroid-induced diabetes. His medication regimen included prednisone, 20 mg twice daily, which he had been taking for the preceding four months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A chest CT (see figures below and on p. 24) demonstrated advanced, Stage IV pulmonary sarcoidosis with significant architectural distortion related to multiple mycetomas visualized in the left upper lobe, right middle lobe and right upper lobe, and markedly distorted bronchiectatic airways connecting to the dominant mycetomas. Pulmonary angiography localized bleeding from both bronchial arteries, as well as a branch of the right bronchial artery, which was supplying the right upper lobe. Interventional radiology performed successful particle embolization of the culprit arteries.

Pulmonary hypertension is commonly seen in Stage IV sarcoidosis, & steroids have not been shown to result in a significant hemodynamic response in this subset of patients. Thus, the role of steroids in advanced stage IV disease is limited.

Laboratory studies were significant for a positive Platelia (ELISA for Aspergillus) of 5.27 (index ≥0.5 is positive) and Fungitell assay greater than 500 pg/mL (glucan values ≥80 pg/mL are positive), confirming aspergillosis. Voriconazole therapy was initiated, and the patient was discharged home with a steroid taper schedule. After further evaluation, he underwent lung transplantation two months later.

An axial CT view demonstrating a large mycetoma in the right upper lobe and a left upper lobe cavitating lung lesion.

An axial CT view demonstrating a large mycetoma in the right upper lobe and a left upper lobe cavitating lung lesion.

An axial CT view demonstrating a mycetoma in the right lower lobe.

An axial CT view demonstrating a mycetoma in the right lower lobe.

An axial CT view demonstrating a mycetoma in the right middle lobe.

An axial CT view demonstrating a mycetoma in the right middle lobe.

Discussion

Asymptomatic pulmonary sarcoidosis, regardless of stage, does not require the initiation of steroid therapy, but rather should be monitored for clinical progression. Steroids should be considered in patients with significant symptoms (e.g., cough, dyspnea, hemoptysis), worsening radiographic findings and worsening pulmonary function tests.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Clinical, Corticosteroid, health risk, hemoptysis, hypertension, mycetomas, patient care, pulmonary sarcoidosis, Research, Steroid, therapy, Treatment, usageIssue: November 2016

You Might Also Like:
  • E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • 2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment
  • E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)